Trine Damgaard
Research Subjects
Research Interests
Trine Damgaard has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
- Joanna Caroline Neill
Division of Pharmacy & Optometry, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, School of Health Sciences, University of Manchester, Manchester, UK
1 shared publication Niels Plath
H. Lundbeck A/S, In Vivo Neuropharmacology, Copenhagen, Denmark
1 shared publicationSuzanne L. Hansen
Department of Pharmacology and Pharmacotherapy, Faculty of Pharmaceutical Sciences, University of Copenhagen, Copenhagen, Denmark
1 shared publication
Latest Publications
- 19 October 2010
- Published by Springer Nature in Psychopharmacology
- Vol. 214 (2) , 403-413
Extrasynaptic GABAA receptor activation reverses recognition memory deficits in an animal model of schizophrenia
Schizophrenia is a complex psychiatric disorder comprised of three main classes of symptoms: positive, negative and cognitive symptoms. Currently, no approved treatment exists for the cognitive symptoms. There is thus a great need for research aiming at identifying novel targets for treatment of this indication. Several neurotransmitter systems are affected in schizophrenia patients, including the γ-amino butyric acid (GABAergic) system, demonstrated by reduced parvalbumin-containing interneurons, glutamate decarboxylase (GAD) and the GABA transporter GAT-1. Furthermore, gene expression of several GABAA receptor sub-units, such as α1, α4 and δ is reduced in the dorsolateral prefrontal cortex of schizophrenia patients.
- 19 October 2010
- Published by Springer Nature in Psychopharmacology
- Vol. 214 (2) , 403-413
Extrasynaptic GABAA receptor activation reverses recognition memory deficits in an animal model of schizophrenia
Schizophrenia is a complex psychiatric disorder comprised of three main classes of symptoms: positive, negative and cognitive symptoms. Currently, no approved treatment exists for the cognitive symptoms. There is thus a great need for research aiming at identifying novel targets for treatment of this indication. Several neurotransmitter systems are affected in schizophrenia patients, including the γ-amino butyric acid (GABAergic) system, demonstrated by reduced parvalbumin-containing interneurons, glutamate decarboxylase (GAD) and the GABA transporter GAT-1. Furthermore, gene expression of several GABAA receptor sub-units, such as α1, α4 and δ is reduced in the dorsolateral prefrontal cortex of schizophrenia patients.